Personalized Medicine

Chapter One: High-Performance Affinity Chromatography: Applications in Drug–Protein Binding Studies and Personalized Medicine

• Abstract
• 1 Introduction
• 2 Frontal Analysis Studies of Drug–Protein Interactions
• 3 Zonal Elution Studies of Drug–Protein Interactions
• 4 Other Methods for Examining Drug–Protein Interactions
• 5 Conclusion
• Acknowledgments

Chapter Two: Role of Proteomics in the Development of Personalized Medicine

• Abstract
• 1 Introduction
• 2 Protein Biomarkers
• 3 Protein Biochips
• 4 Role of Proteomics-Based Molecular Diagnostics in Personalized Medicine
• 5 Pharmacoproteomics
• 6 Concluding Remarks About Application of Proteomics for Personalized Medicine

Chapter Three: Metabolomics and Personalized Medicine

• Abstract
• 1 Introduction
• 2 The Value of “Omics” Technologies in the Development of Personalized Medicine
• 3 What is Metabolomics?
• 4 The Application of Metabolomics Toward Personalized Medicine
• 5 Concluding Remarks
• Acknowledgments

Chapter Four: Clinical Perspectives on Targeting Therapies for Personalized Medicine

• Abstract
• 1 Introduction
• 2 What Are Personalized Medicines?
• 3 Rare Diseases
• 4 Evidence for Precision Medicines from Real World Data
• 5 Using “Real World” Data
• 6 Ethical Concerns
• 7 Adaptive Trial Design
• 8 Companion Diagnostics
• 9 Biological Treatments
• 10 Case Studies: Targets for Precision Medicines and Companion Diagnostics
• 11 Network Pharmacology
• 12 Future Developments
• Acknowledgments

Chapter Five: Personalized Medicine in Respiratory Disease: Role of Proteomics

• Abstract
• 1 Introduction
• 2 Personalized Medicine
• 3 Proteomics
• 4 Respiratory Proteomics
• 5 Asthma
• 6 Chronic Obstructive Pulmonary Disease
• 7 Idiopathic Pulmonary Fibrosis
• 8 Aspirin-Exacerbated Respiratory Disease
• 9 Cystic Fibrosis
• 10 Lung Cancer
• 11 Conclusions
• Acknowledgments

Chapter Six: Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop

• Abstract
• 1 Introduction
• 2 Currently Approved Products Targeting Protein Kinases in Oncology
• 3 Tumor Heterogeneity
• 4 Computational Methods for Identifying Driver Mutations
• 5 Literature Mining in Oncology Research
• 6 Precise Genome Editing
• 7 Conclusion
• Supplementary Material

Chapter Seven: Molecular Dynamics: New Frontier in Personalized Medicine

• Abstract
• 1 Introduction
• 2 Single Nucleotide Polymorphisms in Drug Response
• 3 Drug Discovery
• 4 Advent of Personalized Medicine
• 5 Evolution of Molecular dynamics in the Field of Macromolecule and Binding Interaction Analysis
• 6 Molecular Dynamics—A Boon in Personalized Medicine
• 7 MD Trajectories Analysis
• 8 Application of MD in SNP Analysis Toward Drug Discovery
• 9 Plausible Ways to Overcome the Disadvantages of Molecular Dynamics
• 10 Conclusion
• Acknowledgments

Chapter Eight: Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment

• Abstract
• 1 Introduction
• 2 LSDs Classification
• 3 Treatment of LSDs
• 4 Pharmacological Chaperones Versus Chemical Chaperones
• 5 Combination Therapy for LSDs
• 6 How Can PCT Personalized?
• 7 Computational Studies in PCT
• 8 Advantages and Disadvantages of Various Therapies in LSDs
• 9 Future of PCTs
• 10 Conclusion
• Acknowledgments

Chapter Nine: Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach

• Abstract
• 1 Introduction
• 2 Materials and Methods
• 3 Results
• 4 Discussion
• 5 Conclusion
• Acknowledgments

Chapter Ten: Role of von Willebrand Factor—A1 Domain Variants P1266L, H1268D, C1272R, and C1272F in VWD: A Molecular Modeling and Simulation Analysis Approach

• Abstract
• 1 Introduction
• 2 Material and Methods
• 3 Results
• 4 Discussion
• 5 Conclusion
• Acknowledgment